Skip to main content
OpenTrials
Completed

NCT Number: NCT05077930

Convalescent Plasma Therapy for Hospitalized Patients With COVID-19

Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19. The efficacy of high-titer convalescent plasma for COVID-19, however, still unclear. The present study aims to evaluate the efficacy and safety of using convalescent plasma for treating hospitalized patients with COVID-19.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Maternidade e Cirurgia Nossa Senhora do Rocio/ SA - Hospital do Rocio

Campo Largo, Paraná, 83606-177, Brazil

About this study

This is an open-label, randomized controlled trial aimed to evaluate the efficacy and safety of using convalescent plasma for treating hospitalized patients with COVID-19. Participants must be adult hospitalized patients with a confirmed diagnosis of COVID-19 and time Between symptom onset and inclusion ≤ 7 days. Two hundred participants will be randomized in a 1:1 ratio to receive either 200-400 mL of high-titer COVID-19 convalescent plasma or standard care. The primary endpoint is the proportion of patients with clinical improvement at day 14 following randomization, defined by an increase of two points in the 7-point ordinal scale based on that recommended by the World Health Organization. Safety will be daily assessed by monitoring the occurrence of adverse effects and reactions to convalescent plasma transfusion. Study visits will occur on Day 1, Day 3, Day 7, and Day 14 or until hospital discharge, whichever comes first.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospitalized patients aged ≥18 years.
  • Confirmed diagnosis of COVID-19 by RT-PCR or antigen test in respiratory samples.
  • Time between symptom onset and inclusion ≤ 7 days.
  • Enrolled within 5 days of hospitalization.
  • Sign the consent form.

Exclusion criteria

  • Contraindication to transfusion due to inability to tolerate additional fluid, such as due to decompensated congestive heart failure.
  • History of previous severe allergic reactions to transfused blood products.
  • Limiting comorbidity for administering the therapies provided for in this protocol in the opinion of the investigator.
  • Not currently enrolled another interventional clinical trial of COVID-19 treatment.
  • Critically ill patient with COVID-19 being treated in intensive care.

Treatment and study plan

Convalescent Plasma

Biological

The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.

Standard of care

Drug

The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.

Primary outcomes

  1. Clinical status on a 7-point ordinal scale

    Time frame: From randomization to end of study at Day 14

    Patients' clinical status over time assessed by a 7-point ordinal scale from World Health Organization (WHO). Lower scores are seen with better clinical outcomes. The scale categories are as follows: (1), not hospitalized with resumption of normal activities; (2), not hospitalized, but unable to resume normal activities; (3), hospitalized, not requiring supplemental oxygen; (4), hospitalized, requiring supplemental oxygen; (5), hospitalized, requiring high-flow oxygen therapy or noninvasive mechanical ventilation; (6), hospitalized, requiring ECMO (extracorporeal membrane oxygenation), IMV (intermittent mandatory ventilation), or both; (7), death.

    Proportion of patients with clinical improvement, defined by an increase of two points in the ordinal scale of seven WHO categories.

Secondary outcomes

  1. Percentage of participants at each clinical status on a 7-point ordinal scale

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

    Measure of patients' clinical status using an ordinal scale for clinical improvement created by World Health Organization (WHO) and based on 7-point scale categories. Lower scores in this scale are seen with better clinical outcomes. The scale categories are as follows: (1), not hospitalized with resumption of normal activities; (2), not hospitalized, but unable to resume normal activities; (3), hospitalized, not requiring supplemental oxygen; (4), hospitalized, requiring supplemental oxygen; (5), hospitalized, requiring high-flow oxygen therapy or noninvasive mechanical ventilation; (6), hospitalized, requiring ECMO, IMV, or both; (7), death.

  2. Oxygen saturation

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  3. Prevalence of oxygen-intake methods

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

    Percentage of participants using oxygen by mask or nasal prongs, oxygen by non-invasive ventilation or high flow, intubation & mechanical ventilation and ECMO.

  4. Respiratory rate

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  5. The PaO2 / FiO2 ratio (for patients on mechanical mechanisms)

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  6. Number and /or extension of affected lung areas on chest computed tomography

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  7. Length of hospital stay

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  8. Length of stay in intensive care

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  9. Time until independence from oxygen therapy in days

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  10. Ventilator free days

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  11. In patients who needed mechanical ventilation, time to initiate mechanical ventilation (calculated in days, from entry into the protocol until orotracheal intubation)

    Time frame: Day 1, Day 3, Day 7, and Day 14 after randomization

  12. Rate of transfusion reactions to convalescent plasma infusion

    Time frame: Daily, until Day 14 after randomization

  13. Percentage of participants who develop serious adverse events and adverse events considered as definitely or probably associated with plasma transfusion

    Time frame: Daily, until Day 14 after randomization

    Adverse events (worsening anemia, urticaria, skin rash, transfusion-associated circulatory overload, and others) assessed during hospitalization.

Other outcomes

  1. Association between the presence of comorbidities at baseline and clinical status on a 7-point ordinal scale

    Time frame: Day 1 and Day 14 after randomization

    Association between patients' clinical status assessed by a 7-point ordinal scale from World Health Organization (WHO) on Day 14 after randomization and baseline characteristics and history or comorbidities known at high risk for COVID-19 (age, sex, obesity - body mass index >30 kg/m², history of hypertension, chronic heart disease, congestive heart failure, chronic bronchopulmonary disease, diabetes mellitus, and immunosuppression).

    Lower scores in this scale are seen with better clinical outcomes. The scale categories are as follows: (1), not hospitalized with resumption of normal activities; (2), not hospitalized, but unable to resume normal activities; (3), hospitalized, not requiring supplemental oxygen; (4), hospitalized, requiring supplemental oxygen; (5), hospitalized, requiring high-flow oxygen therapy or noninvasive mechanical ventilation; (6), hospitalized, requiring ECMO, IMV, or both; (7), death.

  2. Association between the volume of convalescent plasma transfused and clinical status on a 7-point ordinal scale

    Time frame: Day 1 and Day 14 after randomization

    Association between patients' clinical status assessed by a 7-point ordinal scale from World Health Organization (WHO) on Day 14 after randomization and the volume of a single unit of convalescent plasma transfused (200 mL or 400 mL). Lower scores in this scale are seen with better clinical outcomes. The scale categories are as follows: (1), not hospitalized with resumption of normal activities; (2), not hospitalized, but unable to resume normal activities; (3), hospitalized, not requiring supplemental oxygen; (4), hospitalized, requiring supplemental oxygen; (5), hospitalized, requiring high-flow oxygen therapy or noninvasive mechanical ventilation; (6), hospitalized, requiring ECMO, IMV, or both; (7), death.

  3. Changes from baseline in inflammatory surrogate markers: white blood counts, lymphocyte counts, C-reactive protein (CRP) and D-dimer levels

    Time frame: Day 1 and Day 14 after randomization

  4. Association between the concentration of inflammatory surrogate markers and clinical status on a 7-point ordinal scale

    Time frame: Day 14 after randomization

    Association between patients' clinical status assessed by a 7-point ordinal scale from World Health Organization (WHO) on Day 14 after randomization and inflammatory surrogate markers, which include white blood counts, lymphocyte counts, C-reactive protein (CRP) and D-dimer levels. Lower scores in this scale are seen with better clinical outcomes. The scale categories are as follows: (1), not hospitalized with resumption of normal activities; (2), not hospitalized, but unable to resume normal activities; (3), hospitalized, not requiring supplemental oxygen; (4), hospitalized, requiring supplemental oxygen; (5), hospitalized, requiring high-flow oxygen therapy or noninvasive mechanical ventilation; (6), hospitalized, requiring ECMO, IMV, or both; (7), death.

Sponsors and collaborators

Lead sponsor

Tânia Portella Costa

Other

Collaborators

  • Centro de Hematologia e Hemoterapia do Paraná - Hemepar
  • Fundação Oswaldo Cruz, Instituto Carlos Chagas, ICC Paraná
  • Science Valley Research Institute

Registry information

Official study title

Validation Protocol for The Clinical Use of Convalescent Plasma for Hospitalized Patients With COVID-19. A Prospective Study at a Hospital in Southern Brazil.

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Oct 14, 2021
Registry last updated
Nov 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.